Treatment of Obesity SAJIDA AHAD MERCY GENERAL SURGERY
|
|
- Ross Doyle
- 5 years ago
- Views:
Transcription
1 Treatment of Obesity SAJIDA AHAD MERCY GENERAL SURGERY
2 Objectives 1. Learn classification and evaluation of overweight and obese patient 2. Discuss impact of voluntary weight loss on morbidity and mortality 3. Review resources for treatment of obesity in primary care setting 4. Update on bariatric surgery
3 Why care about obesity? Obesity is a global public health concern Prevalence of obesity in the United States: 35% among men and 40% among women Compared to 25 years ago when less than 15% of the nation was considered obese The obesity epidemic has placed an economic burden on the US health care system
4 In 2013, obesity was officially recognized as a disease state by the American Medical Association World Health Organization (WHO) defines body mass index (BMI)as follows Normal = 18.5 to 24.9 Overweight =25 to 29.9 Obese >30 class I =30 to 34.9 class II =35 to 39.9 class III = 40 and above
5 Classification and evaluation of overweight and obese patients Clinical classification Size and number of fat cells In adults, upper limits of the total of normal fat cells range from billion The number of fact cell increase most rapidly during late childhood and puberty The number of fat cells can increase 3-5 fold with obesity occurs in childhood or adolescence Hypertrophic obesity Large fat cells correlate with android or truncal fat distribution This condition is often associated with metabolic disorders such as glucose intolerance, dyslipidemia, hypertension and coronary artery disease
6 Fat distribution Fat distribution is important because increased visceral fat predict the development of health risks better than total body fat Waist circumference CT MRI
7 Waist circumference(wc) WC has been shown to be a strong correlate of intra-abdominal adipose tissue in diverse race/ethnic groups WC is very strongly related to total adiposity and Visceral adiposity Visceral fat is associated with many metabolic risk factors, metabolic syndrome, diabetes, and CAD cutoff values for WC (90 cm for men and 83 cm for women) that are equivalent to a BMI of 25 kg/m2 might represent appropriate action levels for counseling patients to limit further weight gain
8 Natural history of obesity Individuals can become overweight at any age One third of the overweight adults do so before age 20 Predictors of weight gain Incidence of diabetic mother R mother who smoked Overweight parents Overweight in childhood Lower education or income group Cessation of smoking Sedentary lifestyle Low metabolic rate Lack of maternal knowledge of child s sweets eating habits Recent marriage Multiple births
9 Cost of obesity The economic cost of obesity The cost-effectiveness of treatment modalities
10 Economic cost of obesity Direct Medical Cost -direct treatment of obesity and related disease e.g. DM and HTN -include medications and surgical procedures Direct Non Medical Cost -expense of health education -expense of maintaining healthy life style -preventing obesity -not paid for by healthcare systems Indirect Cost -time lost from employment -time lost by family and friends
11 Cost of Obesity (contd) In USA, estimated cost of obesity ranges from $26.6 to $ 70 Billion Upto 7 % of annual healthcare expenditures Majority of the cost is treating obesity related conditions rather than obesity itself Cost to employers Medical charges for obese employees 69% higher than non obese employees Obese employees use twice as many sick leave days as normal weight employees Cost to individuals Shorter life expectancy Lower health related quality of life Cost of weigh management and control($66 billion market)
12 Cost effectiveness of obesity interventions A physician weight loss advice is associated with both fewer calories and fat intake and more exercise to lose weight Weigh WatchersTM might be cost-effective because of its demonstrated effectiveness and the moderate cost Medically supervised programs are expensive, but achieve more weight loss than Weight Watchers in the best scenario Although there is insufficient evidence for the effectiveness of weight loss of inexpensive self-help programs and Internet-based programs, they are potentially cost-effective if the weight loss goal can be achieved
13 Voluntary weight loss voluntary weight loss is considered central to the clinical and public health response to prevent obesity Barriers 1. Perceived ineffective 2. Epidemiological concern with increased mortality 3. Broad ramifications more than a 1/3 adults and more than 2/3 obese adults are trying to lose weight at any given time huge potential of interventions to positively affect health or, waste resources
14 Strategies for voluntary weight loss used by patients most people have a weight loss goal of <10 kg, but about one-fourth would like to lose 15 kg or more only one-fifth report the recommended combination of eating fewer calories and exercising >150 min/wk other methods used skipping meals (17%) attending special programs (7%) eating special products (22%) taking supplements or diet pills (14%) fasting(3%) purging (3%)
15 structured weight loss programs advantage of providing stronger evidence about the cause and effect, dose response, and clinical utility of weight loss interventions limitation is that it frequently test interventions that are either not practical in the real world and/or do not reflect the real ways that people in the community go about weight loss Unknown net effect in the population
16 Effect on diseases Weight loss affect long-term disease incidence and mortality most direct and important effects on insulin sensitivity, glucose tolerance, blood pressure, lipid parameters, and inflammatory factors A 5 kg reduction in weight causes Drop of 4 mmhg systolic blood pressure Drop of 3 mmhg of diastolic blood pressure Decrease of 5 to 8 mg/dl of total and low-density lipoprotein (LDL) cholesterol Decrease of 18 mg/dl of triglyceride Weight loss reduces left ventricular hypertrophy, resting heart rate, increases stroke volume and cardiac output, improves coagulation and fibrinolytic factors, reduces angina symptoms, and consistently improves functional status Decrease in inflammatory markers Improvement in HbA1c
17 Is short term weight loss beneficial? most people who try to lose weight regain weight on average, one-third of peak weight loss is regained in the year following weight loss unclear whether the physiological benefits are maintained over a longenough period of time to reverse preexisting pathology and thus influence long-term health outcomes weight loss is associated with increased bone loss, decreased lean muscle mass, gallstone development, and perhaps, decreased immunity associated with multiple weight loss attempts The reduction in bone loss may be offset by increased physical activity, but concerning in older adults
18 Strong and consistent evidence relates intentional weight loss to reduced incidence of diabetes among high-risk individuals Intentional weight loss has been consistently associated with reduced incidence of hypertension and improved control of blood pressure Weight loss may reduce disability and improve mobility and functioning in daily living among older populations Increasing evidence suggests that intentional weight loss reduces overall mortality and possibly CVD incidence
19 Obesity and Primary Care Obesity is one of the most common medical problem seen by Primary Care Physicians these patients are also more likely to present with other diseases, e.g., hypertension, dyslipidemia, type 2 diabetes, metabolic syndrome In practice, however, obesity is underrecognized and undertreated in the primary care setting Failure to adequately identify the overweight and mildly obese patient, however greater recognition for the moderately to severely obese patient less than half of obese adults are being advised to lose weight by health care professionals
20 Office-Based Obesity Care Health care system geared to treating acute care problems rather than chronic conditions Obesity is a chronic condition
21 Physical environment Equipment Materials Tools Protocols Accessibility and comfort, space, reading and educational material Large BP cuffs, large gowns, Step stools, higher limit scales Educational handouts on diet, exercise, medications, surgery, Pre-visit questionnaires, Fitness trackers, apps Return visit, medications, referral to surgery,dietitian and psychologists
22 Treating obesity Measure height and weight BMI Measure waist circumference assess comorbidities Look for causes of obesity including the use of medications Is the patient ready and motivated to lose weight? If the patient is not ready to lose weight, urge weight maintenance and manage the complications If the patient is ready, agree with the patient on reasonable weight and activity goals and document Involve other professionals(dietitians, therapists, structured programs)
23 Guide to selecting treatment Treatment Diet, exercise, behavior therapy With comorbidities With comorbidities > Pharmacotherapy Surgery With comorbidities +
24
25 Pharmacotherapy Antiobesity pharmacotherapy should be considered as an adjunct to diet and behavioral modification facilitates weight loss or promote long-term weight maintenance Potentially treat comorbid conditions associated with obesity, including prediabetes, type 2 diabetes mellitus (T2D), obstructive sleep apnea, hypertension, and dyslipidemia expected weight loss from obesity pharmacotherapy is 5% to 10% of total body weight (TBW) For patients with severe obesity (class III), multiple medications, in addition to surgical intervention may be considered
26 Phentermine Phentermine was approved by the FDA in 1959 Most commonly prescribed short-term (up to 12 weeks) medication for weight loss Phentermine is primarily Standard adult dose is up to 37.5 mg daily before breakfast Use lowest effective dose first side effects: dizziness, dry mouth, difficulty sleeping, and irritability
27 Orlistat Approved in 1999 by the Orlistat alters fat digestion by inhibiting gastric and pancreatic lipases, causing approximately 30% fecal fat excretion Prescribed 3 times a day at a dosage of 120 mg to be taken with meals A lower-dose formulation containing 60 mg per capsule is available over the counter and sold under the brand name Alli Side : bloating, flatulence, flatus with discharge, and fecal incontinence reduces the absorption of fat-soluble vitamins(a, D, E, K), a multivitamin supplement is advised when treating with this agent
28 Lorcaserin(Belviq) Approved by the FDA in 2012 for long-term weight management Selective serotonin 2c receptor agonist decreases food consumptionand promotes satiety by selectively activating the 5HT-2c receptor on anorexigenic POMC neurons located in the hypothalamus daily dose of 10 mg twice a day Side effects : headaches, dizziness, and nausea, hypoglycemia(reduction in diabetic medication dosage may be needed)
29 PHENTERMINE/TOPIRAMATE (QSYMIA) Approved by the FDA in 2012 Phentermine increases norepinephrine in the hypothalamus, enhancing POMC neuron pathway signaling to increase alpha-msh, which binds to melanocortin 4 receptor and suppresses appetite The exactmechanism of action for weight loss with topiramate is not known 4 dosages: 3.75/23mg (starting dose) 7.5/46mg (treatment dose) 11.25/69mg 15/92 mg (maximumdose a stepwise approach, starting at 3.75/23 mg once daily for 2 weeks before increasing to the recommended dose of 7.5/46 mg once daily Further titration to a maximum dose of 15/92 mg once daily may be considered for individuals who do not achieve 3%weight loss after 12 weeks. If 5% weight loss is not achieved after 12 weeks at 15/92mg per day, then phentermine/topiramate ER dose should be gradually reduced for discontinuation
30 Qsymia(contd) Side effects: paresthesias,dizziness, dysgeusia, and dry mouth Inform women of reproductive age about the increased risk of congenital malformation during the first trimester of pregnancy
31 Liraglutide(Saxenda) Glucagon-like peptide-1 (GLP-1) agonist cause glucose-dependent insulin secretion from pancreatic beta cells to lower glucose levels, suppression of glucagon secretion, and slowing of gastric emptying FDA approved in 2014 Dose up to 3.0 mg once daily Side effects: nausea, vomiting, hypoglycemia and diarrhea, increased lipase, abdominal pain,
32 NALTREXONE /BUPROPION (CONTRAVE FDA approved in 2014 Given the known individual effects of naltrexone and bupropion on addiction (alcohol and smoking, respectively), a fixed combination was hypothesized to induce weight loss through sustained modulation of central nervous system reward pathways
33 Gelesis Each capsule contains thousands of proprietary, biocompatible hydrogel particles synthesized with starting materials that are Generally Recognized as Safe by the FDA capsules are taken before a meal with water, after which the small particles within the capsules hydrate and expand in the stomach and small intestine,triggering several important satiety and glycemic control mechanisms built-in safety features: (a) the volume it creates is limited by the amount of water consumed (b) the hydrated particles, which are 2 mm in size, do not cluster or stick together and have similar elasticity (rigidity) as ingested food (c) the particles partially degrade in the colon, releasing absorbed water Pilot Human Study initiation is planned in 2019
34 Bariatric Surgery at Mercy Medical Center Numbers Sleeve gastrectomy :113 Gastric Bypass: 22
35 Before LBS
36 After 175 LBS
37 Program Start Date December 26, 2016 SUCCESS STORIES Program Start Weight lbs Starting BMI Sleeve Gastrectomy May 30, 2017 Current Weight 175 lbs Current BMI 28 Total Weight Loss lbs Starting Pant Size 26 Current Pant Size 10/12 Before After
38 Before 258 LBS
39 After 150 LBS
40 Program Start Date July 10, 2017 SUCCESS STORIES Program Start Weight lbs Starting BMI 43.6 Sleeve Gastrectomy November 28, 2017 Current Weight 150 lbs Current BMI Total Weight Loss 108 lbs Starting Pant Size 18/20 Current Pant Size 6/8
41 Before 442 LBS
42 After LBS
43 Program Start Date September 29, 2016 SUCCESS STORIES Program Start Weight lbs Starting BMI Sleeve Gastrectomy April 18, 2017 Current Weight lbs Current BMI Total Weight Loss lbs Before After
44 320 LBS Before
45 After 135 LBS
46 Success Stories Program Start Date March 30, 2017 Program Start Weight lbs Starting BMI Sleeve Gastrectomy September 20, 2017 Current Weight 135 lbs Current BMI Total Weight Loss 185 lbs
WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM?
WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM? THE OBESITY MEDICINE ASSOCIATION S DEFINITION OF OBESITY Obesity is defined as a chronic, relapsing, multi-factorial, neurobehavioral disease, wherein
More informationManagement of Obesity. Objectives. Background Impact and scope of Obesity. Control of Energy Homeostasis Methods of treatment Medications.
Medical Management of Obesity Ben O Donnell, MD 1 Objectives Background Impact and scope of Obesity Control of Energy Homeostasis Methods of treatment Medications 2 O'Donnell 1 Impact of Obesity According
More informationUnderstanding Obesity: The Causes, Effects, and Treatment Options
Understanding Obesity: The Causes, Effects, and Treatment Options Jeffrey Sicat, MD, FACE Virginia Association of Clinical Nurse Specialists September 29, 2017 Objectives By the end of this discussion,
More informationObesity D R. A I S H A H A L I E K H Z A I M Y
Obesity D R. A I S H A H A L I E K H Z A I M Y Objectives Definition Pathogenesis of obesity Factors predisposing to obesity Complications of obesity Assessment and screening of obesity Management of obesity
More informationObjectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015
Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Presentation downloaded from http://ce.unthsc.edu Objectives Understand that the obesity epidemic is also affecting children and adolescents
More informationWhat Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels?
What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? Daniel Bessesen, MD Professor of Medicine University of Colorado School of Medicine Chief of Endocrinology,
More informationOverview of Management of Obesity
Overview of Management of Obesity Srividya Kidambi, MD, MS Division of Endocrinology, Metabolism, and Clinical Nutrition Medical College of Wisconsin, Milwaukee, WI I have nothing to disclose. Objectives
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationAn Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD
An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD Sanford I. Weill Professor of Metabolic Research Director of the Comprehensive Weight Control Program Weill Cornell Medical College
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationThe prevalence of obesity in adults has doubled over the past 30 years
Obesity in America: Facts and Fiction MICHAEL G. PERRI, PhD Professor, Clinical and Health Psychology Interim Dean, College of Public Health and Health Professions University of Florida Overview: Key Questions
More informationThe New Trend of Anti-Obesity Drug
2016 년대한당뇨병학회춘계학술대회 The New Trend of Anti-Obesity Drug MIN-SEON KIM ASAN MEDICAL CENTER Conflict of Interest Nothing to declare Index Introduction: Obesity Epidemiology, Pathophysiology and Comorbidity
More informationOBESITY IN PRIMARY CARE
OBESITY IN PRIMARY CARE Obesity- definition Is a chronic disease In ICD 10 E66 Overweight and obesity are defined as abnormal or excessive fat accumulation that may impair health. Obesity is a leading
More informationLearning Objectives. Currently Available Options. Update on Weight Loss Pharmacotherapy. Dan Bessesen, MD
Update on Weight Loss Pharmacotherapy Dan Bessesen, MD Daniel.bessesen@ucdenver.edu Learning Objectives List the medications that are currently available for the treatment of obesity, describe their mechanisms
More informationObesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
More informationDisclosures OBESITY. Overview. Obesity: Definition. Prevalence of Obesity is Rising. Obesity as a Risk Factor. None
Disclosures None OBESITY Florencia Halperin, M.D. Medical Director, Program for Management Brigham and Women s Hospital Instructor in Medicine, Harvard Medical School Overview Obesity: Definition Definition
More informationRealistic Expectations: Drugs in the Treatment of Obesity. Lora Cotton, D.O. January 20, 2013
Realistic Expectations: Drugs in the Treatment of Obesity Lora Cotton, D.O. January 20, 2013 Overview Approach FDA approved agents will be covered FDA approval guidelines Candidates Expectations Mechanisms,
More informationEffective Interventions in the Clinical Setting: Engaging and Empowering Patients. Michael J. Bloch, M.D. Doina Kulick, M.D.
Effective Interventions in the Clinical Setting: Engaging and Empowering Patients Michael J. Bloch, M.D. Doina Kulick, M.D. UNIVERSITY OF NEVADA SCHOOL of MEDICINE Sept. 8, 2011 Reality check: What could
More informationPrevention and Management Of Obesity Adolescents & Children
Prevention and Management Of Obesity Adolescents & Children The Pediatric Obesity Prevention and Treatment Toolkit is available at: https://www.optimahealth.com/providers/clinical-reference/pediatric-obesity-prevention-andtreatment-toolkit
More informationWhen Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity
When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity Casey Bonaquist, DO Saturday, April 30 th, 2016 17 th Annual Primary Care & Cardiovascular Symposium Learning Objectives After
More informationAn Introduction to Bariatric Surgery
An Introduction to Bariatric Surgery What is bariatric surgery? Bariatric surgery is a treatment used to help people with obesity manage their health and weight. Why use surgery to manage obesity? Obesity
More informationDeveloping nations vs. developed nations Availability of food contributes to overweight and obesity
KNH 406 1 Developing nations vs. developed nations Availability of food contributes to overweight and obesity Intake Measured in kilojoules (kj) or kilocalories (kcal) - food energy Determined by bomb
More informationObesity the global epidemic
Obesity the global epidemic Obesity the global epidemic 35% 35% 35% 34% 34% 33% 33% 33% 32% 43% Top 10 obese countries Smoking Obesity Alcohol Inf. Diseases Toxins Vehicle Collisions Firearms Death Sexual
More informationKnow Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up
Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:
More informationFor Personal Use Only. Any commercial use is strictly prohibited. Role of glucagon-like peptide 1 receptor agonists in management of obesity
Role of glucagon-like peptide 1 receptor agonists in management of obesity Diana Isaacs, Pharm.D., BCPS, BC-ADM, CDE, Chicago State University, Chicago, IL, and Oak Lawn VA Clinic of Edward Hines Jr. VA
More informationStandards of Care in Diabetes What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE
Standards of Care in Diabetes 2016-- What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE Terminology No longer using the term diabetic. Diabetes does not define people. People
More informationTo see a description of the Academy Recommendation Rating Scheme (Strong, Fair, Weak, Consensus, Insufficient Evidence) visit the EAL.
WWW.ANDEAL.ORG HEART FAILURE HF: EXECUTIVE SUMMARY OF RECOMMENDATIONS (2017) Executive Summary of Recommendations Below are the major recommendations and ratings for the Academy of Nutrition and Dietetics
More informationSmoking cessation and weight gain
Smoking cessation and weight gain David McFadden, MD, MPH Mayo Clinic Nicotine Dependence Center 2012 MFMER slide-1 Disclosures I presented lectures for Pfizer-sponsored tobacco treatment seminars in Brazil,
More informationMetabolic Syndrome: What s so big about BIG?
Tuesday, 10:00 11:30, A2 Objectives: Notes: Metabolic Syndrome: What s so big about BIG? Patrice Conrad pbconrad1@att.net 1. Identify advances in clinical assessment and management of selected healthcare
More informationAnti-Obesity Agents Drug Class Prior Authorization Protocol
Anti-Obesity Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: March 1, 2018 This policy has been developed through review
More informationObesity: Pharmacologic and Surgical Management
Obesity: Pharmacologic and Surgical Management ADRIENNE YOUDIM, MD, FACP ASSOCIATE PROFESSOR OF MEDICINE, UCLA ASSISTANT PROFESSOR OF MEDICINE, CEDARS SINAI MEDICAL CENTER JANUARY 2018 Defining Obesity
More informationObesity Management in Type 2 Diabetes
Obesity Management in Type 2 Diabetes Clare J. Lee, MD, MHS Assistant Professor of Medicine, Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins University Disclosures None Objectives Describe
More informationWHAT S THE SKINNY ON WEIGHT LOSS MEDICATION SAFETY? January 25, 2019 Pennsylvania Pharmacists Association
WHAT S THE SKINNY ON WEIGHT LOSS MEDICATION SAFETY? January 25, 2019 Pennsylvania Pharmacists Association MEGAN N DUNLOP, PHARMD, CTTS CLINICAL PHARMACIST, UPMC COMMUNITY PROVIDER SERVICES LEARNING OBJECTIVES
More informationImplications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?
Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator
More informationViriato Fiallo, MD Ursula McMillian, MD
Viriato Fiallo, MD Ursula McMillian, MD Objectives Define obesity and effects on society and healthcare Define bariatric surgery Discuss recent medical management versus surgery research Evaluate different
More informationInternational Journal of Pharma and Bio Sciences COMPARISON OF EFFICACY AND SAFETY OF RIMONABANT WITH ORLISTAT IN OBESE AND OVERWEIGHT PATIENTS
International Journal of Pharma and Bio Sciences RESEARCH ARTICLE PHARMACOLOGY COMPARISON OF EFFICACY AND SAFETY OF RIMONABANT WITH ORLISTAT IN OBESE AND OVERWEIGHT PATIENTS Corresponding Author DR.JAIN
More informationOverweight and Obesity on the Menu. Marwan Akel, Pharm. D, MPH Clinical Assistant Professor School of Pharmacy Lebanese International University
Overweight and Obesity on the Menu Marwan Akel, Pharm. D, MPH Clinical Assistant Professor School of Pharmacy Lebanese International University Prevention The most efficient and cost-effective approach
More informationLearning Objectives 11/8/2014. Obesity: Strategies to Tackle the Epidemic MA ACP Annual Scientific Meeting 1. Body Mass Index Calculation
Fatima Cody Stanford, MD, MPH Obesity Medicine & Nutrition Massachusetts General Hospital Harvard Medical School Learning Objectives Review the prevalence of obesity in the USA Outline pathogenesis and
More informationI. ALL CLAIMS: HEALTH CARE PROFESSIONALS
HCP Prescribing Information Date/Version January 2015 Version 2 Page: 1 of 5 I. ALL CLAIMS: HEALTH CARE PROFESSIONALS Indications and Usage Saxenda (liraglutide [rdna origin] injection) is indicated as
More informationStandards of Medical Care in Diabetes 2016
Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking
More informationOrlistat. How Alli really affects you during weight loss. JD Welch
Orlistat How Alli really affects you during weight loss JD Welch HE 426 Tom Kelly November 24, 2008 Classification and Usage Orlistat is the first drug approved by the Food and Drug Administration (FDA)
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1172-3 Program Prior Authorization - California and New York Regulatory Program - Weight Loss Medication Includes both brand and
More informationWeight Loss Surgery Program
Weight Loss Surgery Program More than 500,000 Americans die prematurely each year from obesity-related complications, and it is one of the leading causes of preventable death. If you want to do something
More informationTreating Patients with PRE- DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background
Treating Patients with PRE- DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationReview of Pharmacologic Weight Loss Medications in a Patient-Centered Medical Home
604858PMTXXX10.1177/8755122515604858Journal of Pharmacy TechnologyCostello et al research-article2015 Case report Review of Pharmacologic Weight Loss Medications in a Patient-Centered Medical Home Journal
More informationDisclosures. Objectives. Impact of Obesity in Primary Care Practice and What To Do About It. Intuitive Surgical. Consultant
Disclosures Intuitive Surgical Consultant Stephen Archer, MD, FACS, FASMBS Director, Bariatric Surgery, St. Charles Medical Center Bend, OR Grand Rounds June 15, 2018 2 Objectives Impact of Obesity in
More informationWithout Background for printing as Pocket Reference
Without Background for printing as Pocket Reference Diabetes Prevention Program 1 LOOK AHEAD 3 Multi-center trial in patients with impaired glucose tolerance Weight loss of 7% reduced the rate of progression
More informationDietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes. Stephen D. Sisson MD
Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes Stephen D. Sisson MD Objectives To review dietary recommendations in the following conditions: Obesity Hypertension Diabetes
More informationThe ABCDs of Obesity
The ABCDs of Obesity Adipose Based Chronic Disease Michael A. Bush, M.D. Clinical Chief, Division of Endocrinology Cedars-Sinai Medical Center Clinical Associate Professor, Geffen School of Medicine, UCLA
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationIndex. Page references in bold refer to figures and page references in italic refer to tables.
Page references in bold refer to figures and page references in italic refer to tables. Adrenaline, high-fat response in post-obese 142 Alcohol absorption 11-12 balance equation 17 and obesity 10-11 thermogenesis
More informationPart 1: Obesity. Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes 10/15/2018. Objectives.
Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes Stephen D. Sisson MD Objectives To review dietary recommendations in the following conditions: Obesity Hypertension Diabetes
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationFDA approves Belviq to treat some overweight or obese adults
FDA approves Belviq to treat some overweight or obese adults Silver Spring, MD, USA (June 27, 2012) - The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition
More informationPharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018
Pharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018 Disclosures Faculty Assistant Clinical Professor, Department of Medicine,
More informationEnergy balance. Factors affecting energy input. Energy input vs. Energy output Balance Negative: weight loss Positive: weight gain
1 Energy balance Energy input vs. Energy output Balance Negative: weight loss Positive: weight gain Special implications Infancy, Illness, Pregnancy & Lactation, Sports Factors affecting energy input neuro-endocrine
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationManaging Obesity as a Disease. Disclosure. Objectives
Managing Obesity as a Disease Ji Hyun Chun (CJ), PA-C, BC-ADM OptumCare Medical Group: Endocrinology, Irvine, CA President, American Society of Endocrine PAs none Disclosure Objectives Recognize obesity
More informationReduce hunger and help control cravings with CONTRAVE
Reduce hunger and help control cravings with CONTRAVE Understanding and identifying patients who are ready to start their weight-loss journey with CONTRAVE is key to helping them reach their weight-loss
More informationObesity Pharmacotherapy: Options and Applications in Clinical Practice. Scott Kahan, MD, MPH
Obesity Pharmacotherapy: Options and Applications in Clinical Practice Scott Kahan, MD, MPH Obesity Pharmacotherapy Few providers prescribe pharmacotherapy. Few patients use pharmacotherapy. Pharmacotherapy
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationObesity and Bariatric Surgery
Obesity and Bariatric Surgery Disclosure Nothing to disclose Subhashini Ayloo MD, MPH, FACS Associate Professor of Surgery Director of MIS HPB/LT Rutgers, New Jersey Medical School March 24 th, 2017 Overview
More informationAdolescent Obesity GOALS BODY MASS INDEX (BMI)
Adolescent Obesity GOALS Lynette Leighton, MS, MD Department of Family and Community Medicine University of California, San Francisco December 3, 2012 1. Be familiar with updated obesity trends for adolescent
More information1 Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. Endocr Pract. 2012;18: Depression. Cancer. Gallbladder Disease
Percent 4 3 2 1 Obese Overweight Extremely obese Note: Age-adjusted by the direct method to the year 2 US Bureau of the Census using age groups 2 39, 4 59, and 6 74 years. Pregnant females excluded. Overweight
More information6/23/2011. Bariatric Surgery: What the Primary Care Provider Should Know. Case Presentation: Rachelle
Bariatric Surgery: What the Primary Care Provider Should Know 2,000 B.C. 2,000 A.D. Case Presentation: Rachelle 35 year-old woman with morbid obesity. 5 1 236 lbs BMI 44.5 PMHx: mild depression obstructive
More informationSubmitted January 13, 2016
Comments from the American Cancer Society and the American Cancer Society Cancer Action Network on the U.S. Preventive Services Task Force Draft Research Plan for Weight Loss to Prevent Obesity-Related
More informationOBESITY:Pharmacotherapy Vs Surgery
OBESITY:Pharmacotherapy Vs Surgery Dr. Ranajit Sen Chowdhury Associate Professor Department of Medicine Sir Salimullah Medical College & Mitford Hospital. 1 Historical Perspective Paleolithic Era > 25,000
More informationMetabolic Syndrome Across the Life Cycle - Adolescent. Joy Friedman MD
Metabolic Syndrome Across the Life Cycle - Adolescent Joy Friedman MD Disclosures I have no actual or potential conflict of interest in relation to this program or presentation. I will mention off-label
More informationNavigating the new weight loss medications Jacqueline Jordan Spiegel, MS, PA-C, DFAAPA Associate Professor Midwestern University
Navigating the new weight loss medications Jacqueline Jordan Spiegel, MS, PA-C, DFAAPA Associate Professor Midwestern University Objectives Discuss the evolution of obesity as a diagnosis and disease.
More informationWhere are We Now? Editor s Note: Who Qualifi es for Obesity Medications?
Obesity Medications Where are We Now? by Christopher D. Still, DO, FACP, FACN, Nadia Boulghassoul-Pietrzykowska, MD, and Jennifer E. Franceschelli, DO Editor s Note: Please note that some of the medications
More informationScience of Obesity (I-2.28)
Science of Obesity (I-2.28) Dr Noha Nooh Lasheen Lecturer of Physiology Date :16 / 10 / 2016 Objectives By the end of this lecture, the student should be able to: Define energy, energy balance and obesity.
More informationSession 6B Appropriate Treatment of Obesity Demonstrates Clinical & Economic Success
Session 6B Appropriate Treatment of Obesity Demonstrates Clinical & Economic Success Part 2 John Dawson, FSA, MAAA Appropriate Treatment of Obesity Demonstrates Clinical & Economic Success SOA Asia-Pacific
More informationHE 250 PERSONAL HEALTH. Fitness
HE 250 PERSONAL HEALTH Fitness 40% of American adults are not physically active 30% of adults only get the recommended amount of exercise 55% of 1 in 4 high schoolers meet the recommendations college students
More informationWhat is obesity? OBESITY. Obesity is a health issue in which someone has so much extra fat that it negatively impacts their health.
OBESITY What is obesity? Obesity is a health issue in which someone has so much extra fat that it negatively impacts their health. Obesity is most often measured by body mass index (BMI), which looks at
More informationCase Study #4: Hypertension and Cardiovascular Disease
Helen Jang Tara Hooley John K Rhee Case Study #4: Hypertension and Cardiovascular Disease 7. What risk factors does Mrs. Sanders currently have? The risk factors that Mrs. Sanders has are high blood pressure
More informationUnderstanding Body Composition
Understanding Body Composition Chapter 7 Body Composition n Body composition is the ratio between fat and fat-free mass n Fat-free mass includes all tissues exclusive of fat (muscle, bone, organs, fluids)
More informationEnergy balance. Factors affecting energy input. Energy input vs. Energy output Balance Negative: weight loss Positive: weight gain
1 Energy balance Energy input vs. Energy output Balance Negative: weight loss Positive: weight gain Special implications Infancy, Illness, Pregnancy & Lactation, Sports Factors affecting energy input neuro-endocrine
More informationSOUND HEALTH & WELLNESS TRUST
WEIGHT LOSS SURGERY POLICY SOUNDPLUS PPO AND SOUND PPO PLANS All procedures approved by the Plan must be pre-authorized by Aetna (the Trust s Utilization Management Vendor) and care must be provided by
More informationHypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents
Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of
More informationOBESITY: The Growing Epidemic and its Medical Impact
OBESITY: The Growing Epidemic and its Medical Impact Ray Plodkowski, MD Co-Chief, Chief, of Division of Medical Nutrition, University of Nevada School of Medicine. Chief, Endocrinology & Metabolism, Sachiko
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationTargeted Nutrition Therapy Nutrition Masters Course
Targeted Nutrition Therapy Nutrition Masters Course Nilima Desai, MPH, RD Learning Objectives Review clinical studies on innovative, targeted nutrition therapies for: o Blood glucose management o Dyslipidemia
More informationWhy Screen at 23? What can YOU do?
Why Screen at 23? Every 1 in 2 Asian American adults has diabetes or prediabetes. More than half of Asian Americans did not know they have type 2 diabetes or prediabetes. Asian Americans can develop diabetes
More informationInterdisciplinary Certification in Obesity and Weight Management Detailed Content Outline
1. Patient Assessment and Development of Treatment Plan (35 Items) A. Patient History and Current Status 1. Collect patient assessment information: a. weight history, including development genetics growth
More informationUsing New Guidelines to Improve Best Practices in Obesity Management
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationMEDICAL MANAGEMENT 101
MEDICAL MANAGEMENT 101 Christopher Still, DO, FACN, FACP Medical Director, Center for Nutrition & Weight Management Director, Geisinger Obesity Research Institute Geisinger Health Care System Your Weight
More informationComplete the Qsymia Healthcare Provider Training Program in 2 easy steps:
Overview FDA has required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia so that healthcare providers can be informed about the increased risk of teratogenicity associated with Qsymia therapy.
More informationUpdate on the Recent Advances in Obesity Management. Benjamin O Donnell, MD Oct 5 th, 2018
Update on the Recent Advances in Obesity Management Benjamin O Donnell, MD Oct 5 th, 2018 Objectives Background Control of Energy Homeostasis Approach to Diet and Exercise Medications Recently Approved
More informationThe O b O e b si s ty y Epi p de d mi m c: Pra r c a tical a Man a ag a e g me m nt App p r p o r a o c a hes O j b e j c e t c iv i es
The Obesity Epidemic: Practical Management Approaches Goutham Rao, MD Chair, Obesity Committee American Heart Association Clinical Associate Professor, University of Chicago Pritzker School of Medicine
More informationIFA Sports Nutrition Certification Test Answer Form
IFA Sports Nutrition Certification Test Answer Form In order to receive your certification card, take the following test and mail this single page answer sheet in with your check or money order in US funds.
More informationDIABETES. A growing problem
DIABETES A growing problem Countries still grappling with infectious diseases such as tuberculosis, HIV/AIDS and malaria now face a double burden of disease Major social and economic change has brought
More informationCravings are one of the main reasons diets fail
? Did you KNOW Cravings are one of the main reasons diets fail Help control your cravings and lose weight with CONTRAVE Actual patient. Results not typical. Across three studies, 46% of patients taking
More informationManipal & Apollo Spectra Hospital. Special Interest:Laparoscopy & Bariatric Surgery
Name: Dr M G Bhat Designation: Consultant Surgeon Affiliation: Manipal & Apollo Spectra Hospital Special Interest:Laparoscopy & Bariatric Surgery When should we suggest Bariatric Surgery in PCOD? 17 June
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationEmpower Preventive Medicine. Timothy J. McCormick, DO, MPH 4221 Baymeadows Suite 6 Jacksonville, FL
Empower Preventive Medicine Timothy J. McCormick, DO, MPH 4221 Baymeadows Suite 6 Jacksonville, FL 32217 904-367-4005 Drtim@emprevmed.com Obesity Medicine Old paradigm: Obesity was a matter of willpower,
More informationHypertension and Hyperlipidemia. University of Illinois at Chicago College of Nursing
Hypertension and Hyperlipidemia University of Illinois at Chicago College of Nursing 1 Learning Objectives 1. Provide a basic level of knowledge regarding hypertension and hyperlipidemia and care coordinators/
More informationObesity Management in Women
Defining Obesity Obesity Management in Women Alka M. Kanaya, M.D. Assistant Professor of Medicine October 19, 2007 An increase in fat accumulation, to the extent that health may be adversely affected BMI
More informationSurgical History Please list all operations and dates:
1 General Information *Please complete in blue or black ink only* Name: Date: Address: City: State: Zip Code: Date of Birth: Email: Telephone: (Cell) (Home) (Work) Referred by: Occupation: Primary Doctor:
More information